VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure

Summary

This trial is seeking to determine whether a single 4mg intranasal dose of bumetanide acutely reduces pulmonary artery pressure and blood volume in the outpatient setting for patients with heart failure and an implanted device for remote patient monitoring (i.e. Cordella or CardioMEMS).

Timeline

Start

2026-01-21

Primary completion

2026-01-21

Completion

2026-01-21

Drugs

Indications